(Q37779809)

23 August 2017

1 reference

title

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease (English)

1 reference

23 August 2017

Harold Bays

1

1 reference

23 August 2017

16 August 2010

1 reference

Expert Review of Cardiovascular Therapy

23 August 2017

1 reference

23 August 2017

8

1 reference

23 August 2017

12

1 reference

23 August 2017

1777-1801

1 reference

Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia

23 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

"Sick fat," metabolic disease, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiposopathy: why do adiposity and obesity cause metabolic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Is adiposopathy (sick fat) an endocrine disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The Adipocyte-Number Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Decreased expression of adipogenic genes in obese subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Spontaneous and experimental human obesity: Effects of diet and adipose cell size on lipolysis and lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Mechanism of insulin-resistant glucose transport activity in the enlarged adipose cell of the aged, obese rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiposopathy is a more rational treatment target for metabolic disease than obesity alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Metabolic and body composition factors in subgroups of obesity: what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Why visceral fat is bad: mechanisms of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Are there persons who are obese, but metabolically healthy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Role of adipose tissue as an inflammatory organ in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous fat cell hypertrophy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adipose tissue dysfunction in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Emerging role of adipose tissue hypoxia in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adipose tissues as an ancestral immune organ: site-specific change in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adipose tissue, adipokines, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Regulation of the plasma non-esterified fatty acid concentration in the postprandial state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

21 January 2018

Metabolic flexibility

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Ceramide content is increased in skeletal muscle from obese insulin-resistant humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Current and investigational antiobesity agents and obesity therapeutic treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Pharmacotherapy of obesity - benefit, bias and hyperbole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adipogenic and antiapoptotic protein levels in human adipose stromal cells after weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adipogenic signaling in rat white adipose tissue: modulation by aging and calorie restriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Measurement of energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Differences in basal energy expenditure and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Simplified resting metabolic rate-predicting formulas for normal-sized and obese individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Leptin: a pivotal regulator of human energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Exercise improves insulin and leptin sensitivity in hypothalamus of Wistar rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Beneficial effects of exercise: shifting the focus from body weight to other markers of health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Weight loss composition: the effects of exercise following obesity surgery as measured by bioelectrical impedance analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Caloric restriction with or without exercise: the fitness versus fatness debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

21 January 2018

Safety of obesity drugs

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Methylphenidate hydrochloride increases energy expenditure in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The effects of amphetamine on body weight and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Effects on weight reduction and safety of short-term phentermine administration in Korean obese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate and type 2 diabetes: an old wine in a new bottle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Monotherapy trials of new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Treatment of obese patients with binge eating disorder using topiramate: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Safety of topiramate: adverse events and relationships to dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Predictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate: a new potential pharmacological treatment for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Weight reducing and metabolic effects of topiramate in patients with migraine--an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

21 January 2018

Ion channels in epilepsy

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate in the treatment of compulsive sexual behavior: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate Normalizes Hippocampal NPY-LI in Flinders Sensitive Line ‘Depressed’ Rats and Upregulates NPY, Galanin, and CRH-LI in the Hypothalamus: Implications for Mood-Stabilizing and Weight Loss-Inducing Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Galanin-Like Peptide Functions More Like Leptin than Like Galanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

A prospective study of body weight and serum leptin levels in patients treated with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Sulfamates and their therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Influence of topiramate in the regulation of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiponectin and energy homeostasis: consensus and controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Drug-induced acute angle closure glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Effect of topiramate on acid-base balance: extent, mechanism and effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Increased propensity for calcium phosphate kidney stones with topiramate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Severe topiramate-associated hyperthermia resulting in persistent neurological dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

CB1 antagonists for obesity--what lessons have we learned from rimonabant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Quality of pharmaceutical industry press releases based on original research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Withdrawal of sibutramine leaves European doctors with just one obesity drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Pharmacological targeting of the serotonergic system for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

Adiponectin acts in the brain to decrease body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.125

21 January 2018

Identifiers

DOI

10.1586/ERC.10.125

1 reference

23 August 2017

1 reference

PubMed ID

20707765